Economic Impact of Elranatamab for Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Elranatamab for RRMM is projected to result in a minimal to small budget impact over 3 years and good economic value with lower cost of care per month of PFS compared with other available RRMM treatments except for ciltacabtagene autoleucel.
Authors
- Alexander Schepart
- Laura Rose Bobolts
- Yannan Hu (ORCID: https://orcid.org/0009-0008-3960-553X)
- Isha Mol (ORCID: https://orcid.org/0009-0009-6366-9178)
- Rickard Sandin
- Patrick Hlavacek (ORCID: https://orcid.org/0000-0002-4752-3218)
- Bhavesh Shah (ORCID: https://orcid.org/0000-0002-6667-525X)
- David Hughes (ORCID: https://orcid.org/0000-0002-0971-7265)
- Yun Liu (ORCID: https://orcid.org/0000-0001-7384-1351)
- John Hart (ORCID: https://orcid.org/0000-0002-8929-2462)
Institutions
- Boston Medical Center (US)
- OncoMed (United States) (US)
- Pfizer (United States) (US)
- Pfizer (Sweden) (SE)
Publication Details
- Journal
- ClinicoEconomics and Outcomes Research
- Published
- 2025-04-01
- DOI
- https://doi.org/10.2147/ceor.s501404
- Citations
- 3
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 9.39
Funders
- Pfizer